An FDA advisory panel has voted against the approval of a lung cancer immunotherapy drug developed and tested in China, The New York Times reported Feb. 10.
Read the full post on Becker's Hospital Review - Healthcare News
FDA panel votes against approval of China-developed cancer drug
